U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879067) titled 'Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers' on March 11.
Brief Summary: The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.
Study Start Date: Nov. 12, 2018
Study Type: INTERVENTIONAL
Condition:
Safety
Tolerability
Intervention:
DRUG: Placebo
Placebo nasal spray
DRUG: Foralumab Nasal
foralumab nasal spray
Recruitment Status: COMPLETED
Sponsor: Tiziana Life Sciences LTD
Publi...